PMID- 35815818
OWN - NLM
STAT- MEDLINE
DCOM- 20220930
LR  - 20221226
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 38
IP  - 10
DP  - 2022 Oct
TI  - Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for 
      the treatment of patients with relapsed or refractory multiple myeloma.
PG  - 1759-1767
LID - 10.1080/03007995.2022.2100651 [doi]
AB  - Objective: In the absence of head-to-head trials, indirect treatment comparisons 
      (ITCs) between ciltacabtagene autoleucel (cilta-cel; in CARTITUDE-1) and 
      treatments used in real-world clinical practice (physician's choice of treatment 
      [PCT]), were previously conducted. We conducted multiple meta-analyses using 
      available ITC data to consolidate the effectiveness of cilta-cel versus PCT for 
      patients with triple-class exposed relapsed or refractory multiple myeloma 
      (RRMM).Methods: Five ITCs were assessed for similarity to ensure robust 
      comparisons using meta-analysis. Effectiveness outcomes were overall survival 
      (OS), progression-free survival (PFS), time to next treatment (TTNT), and overall 
      response rate (ORR). A robust variance estimator was used to account for the use 
      of CARTITUDE-1 in each pairwise ITC. Analyses were conducted in both treated and 
      enrolled populations of CARTITUDE-1.Results: Four ITCs were combined for 
      evaluation of OS. Results were statistically significantly in favor of cilta-cel 
      versus PCT in treated patients (hazard ratio [HR]: 0.24, 95% confidence interval 
      [CI]: 0.22-0.26). Three ITCs were combined for evaluation of PFS and TTNT. 
      Cilta-cel reduced the risk of progression and receiving a subsequent treatment by 
      80% (HR: 0.20 [95% CI: 0.06, 0.70]) and 83% (HR: 0.17 [95% CI: 0.12, 0.26]), 
      respectively. Three ITCs were combined for evaluation of ORR. Cilta-cel increased 
      the odds of achieving an overall response by 86-times versus PCT in treated 
      patients. Findings were consistent in the enrolled populations and across 
      sensitivity analyses.Conclusions: Evaluating multiple indirect comparisons, 
      cilta-cel demonstrated a significantly superior advantage over PCT, highlighting 
      its effectiveness as a therapy in patients with triple-class exposed RRMM.
FAU - Costa, Luciano J
AU  - Costa LJ
AD  - University of Alabama at Birmingham, Birmingham, AL, USA.
FAU - Hari, Parameswaran
AU  - Hari P
AD  - Iovance Biotherapeutics, San Carlos, CA, USA.
FAU - Berdeja, Jesus G
AU  - Berdeja JG
AD  - Sarah Cannon Research Institute, Nashville, TN, USA.
FAU - De Stefano, Valerio
AU  - De Stefano V
AUID- ORCID: 0000-0002-5178-5827
AD  - Section of Hematology, Department of Radiological and Hematological Sciences, 
      Catholic University, Fondazione Policlinico A Gemelli, IRCCS, Rome, Italy.
FAU - Gay, Francesca
AU  - Gay F
AD  - Division of Hematology, University of Torino, Torino, Italy.
FAU - Hooper, Becky
AU  - Hooper B
AUID- ORCID: 0000-0002-0146-5577
AD  - EVERSANA, Sydney, NS, Canada.
FAU - Bartlett, Meaghan
AU  - Bartlett M
AUID- ORCID: 0000-0003-4616-8776
AD  - EVERSANA, Sydney, NS, Canada.
FAU - Haltner, Anja
AU  - Haltner A
AUID- ORCID: 0000-0002-9829-7791
AD  - EVERSANA, Sydney, NS, Canada.
FAU - Rosta, Emily
AU  - Rosta E
AD  - EVERSANA, Sydney, NS, Canada.
FAU - Kumar, Shaji
AU  - Kumar S
AUID- ORCID: 0000-0001-5392-9284
AD  - Mayo Clinic, Rochester, MN, USA.
FAU - Martin, Thomas
AU  - Martin T
AD  - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
FAU - Mateos, Maria-Victoria
AU  - Mateos MV
AUID- ORCID: 0000-0003-2390-1218
AD  - Institute of Cancer Molecular and Cellular Biology, University Hospital of 
      Salamanca, Salamanca, Spain.
FAU - Moreau, Philippe
AU  - Moreau P
AD  - Clinical Hematology, University Hospital Hotel-Dieu, Nantes, France.
FAU - Usmani, Saad Z
AU  - Usmani SZ
AD  - Levine Cancer Institute-Atrium Health, Charlotte, NC, USA.
FAU - Olyslager, Yunsi
AU  - Olyslager Y
AD  - Janssen Pharmaceutica NV, Beerse, Belgium.
FAU - Schecter, Jordan M
AU  - Schecter JM
AD  - Janssen R&D, Raritan, NJ, USA.
FAU - Roccia, Tito
AU  - Roccia T
AD  - Janssen R&D, Raritan, NJ, USA.
FAU - Garrett, Ashraf
AU  - Garrett A
AD  - Legend Biotech USA, Piscataway, NJ, USA.
FAU - Lee, Sam
AU  - Lee S
AD  - Legend Biotech USA, Piscataway, NJ, USA.
FAU - Nesheiwat, Tonia
AU  - Nesheiwat T
AD  - Legend Biotech USA, Piscataway, NJ, USA.
FAU - Pacaud, Lida
AU  - Pacaud L
AD  - Legend Biotech USA, Piscataway, NJ, USA.
FAU - Zhou, Changwei
AU  - Zhou C
AD  - Legend Biotech USA, Piscataway, NJ, USA.
FAU - Samjoo, Imtiaz A
AU  - Samjoo IA
AUID- ORCID: 0000-0003-1415-8055
AD  - EVERSANA, Burlington, ON, Canada.
FAU - Lin, Yi
AU  - Lin Y
AD  - Mayo Clinic, Rochester, MN, USA.
FAU - Diels, Joris
AU  - Diels J
AD  - Janssen Pharmaceutica NV, Beerse, Belgium.
FAU - Valluri, Satish
AU  - Valluri S
AD  - Janssen Global Services, LLC, Raritan, NJ, USA.
FAU - Weisel, Katja
AU  - Weisel K
AD  - University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20220810
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Humans
MH  - *Multiple Myeloma/drug therapy
MH  - *Physicians
OTO - NOTNLM
OT  - CAR-T
OT  - CARTITUDE-1
OT  - Relapsed or refractory multiple myeloma
OT  - ciltacabtagene autoleucel
OT  - meta-analysis
OT  - triple-class exposed
EDAT- 2022/07/12 06:00
MHDA- 2022/10/01 06:00
CRDT- 2022/07/11 07:13
PHST- 2022/07/12 06:00 [pubmed]
PHST- 2022/10/01 06:00 [medline]
PHST- 2022/07/11 07:13 [entrez]
AID - 10.1080/03007995.2022.2100651 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2022 Oct;38(10):1759-1767. doi: 10.1080/03007995.2022.2100651. 
      Epub 2022 Aug 10.